This site is intended for health professionals only

Published on 31 March 2009

Share this story:
Twitter
LinkedIn

Viroblock SA reports positive results of preclinical studies in antiviral nasal spray

teaser

Viroblock SA has announced today that the first generation of
VCCD Tech antiviral nasal spray formulation is active against human influenza.

Viroblock’s patented Cholesterol Catalytic Depletion Technology
(VCCD Tech) inactivates enveloped viruses during the extra-cellular phase, by altering and destabilising cholesterol-rich viral envelopes.

The two pre-clinical studies exposed ferrets to Influenza A
Wisconsin/67/2005 and influenza A Panama/2007/99 strains, and were conducted by Retroscreen Virology Ltd – a recognised leader in the research and testing of antiviral compounds and vaccines.

Both the direct inoculation and the natural transmission protocols have confirmed the effectiveness and the value of the antiviral nasal spray.

These in-vivo campaigns confirm all in laboratory in-vitro
studies to date and demonstrate that VCCD Tech represents a breakthrough for inactivating a number of enveloped viruses and their strains.

“Our depletion technology shows no toxicity at the dosage we
tested thus far and allegedly limits the development of any viral resistance, and makes it effective on all families of enveloped viruses, such as human and avian influenzas, SARS, AIDS, Ebola and smallpox viruses.”

“This is an exciting development period for Viroblock and the
most recent pre-clinical performance is a testament to our innovative and cutting-edge technology, the quality of our team, board of directors and investors.”

“We, at Viroblock, leverage all our technological assets for
rapidly developing the next generation of antiviral nasal sprays; I am also confident that our technology will become an important element of pandemic influenza preparedness efforts”.

“Our ability to deliver tailored antiviral formulations, which
can exist as colloidal suspensions, gels, creams, and aerosol sprays, opens promising business opportunities and a bright future for Viroblock.”, comments CEO Thierry Pelet.

Viroblock



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn